Tilray Brands, Inc. (TLRY) Stock Analysis and Metrics

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic CIK: 0001731348

Market Cap 602.57 Mn

P/E 0.73

P/S 0.70

Div. Yield 0.00

ROIC (Qtr) -0.01

Total Debt (Qtr) 143.82 Mn

Revenue Growth (1y) (Qtr) 11.28

Add ratio to table...

About

Tilray Brands, Inc. is a leading global lifestyle consumer products company that operates at the intersection of cannabis beverage wellness and entertainment. The company develops manufactures markets and sells a diverse portfolio of brands that span alcoholic beverages nonalcoholic drinks craft spirits medical and adult use cannabis products and hemp based foods. Its activities are supported by production facilities in the United States Canada Europe and Latin America and by a distribution network that reaches customers in over 20 countries. Tilray...

Tilray Brands, Inc. is a leading global lifestyle consumer products company that operates at the intersection of cannabis beverage wellness and entertainment. The company develops manufactures markets and sells a diverse portfolio of brands that span alcoholic beverages nonalcoholic drinks craft spirits medical and adult use cannabis products and hemp based foods. Its activities are supported by production facilities in the United States Canada Europe and Latin America and by a distribution network that reaches customers in over 20 countries. Tilray Brands aims to build brand equity and consumer loyalty through high quality products that create memorable experiences.

The company generates revenue primarily from the sale of cannabis beverages and wellness products. In fiscal year 2025 the beverage segment contributed 29 percent of total net revenue the cannabis segment 30 percent the distribution segment 33 percent and the wellness segment 8 percent. Cannabis revenue comes from medical and adult use flower pre rolls vapes topicals edibles and beverages sold in Canada and internationally. Beverage revenue is derived from craft beer spirits and nonalcoholic drinks sold through retail outlets bars restaurants and other venues across the United States and abroad. Wellness revenue stems from hemp based foods proteins seeds and functional beverages sold to retailers wholesalers and direct consumers. Distribution revenue arises from the purchase resale and logistics of pharmaceutical and wellness products including medical cannabis supplied to pharmacies and hospitals in Germany and other markets.

The company operates through the following segments: Beverage Cannabis Distribution Wellness.

• Beverage: This segment produces markets and sells craft beer craft spirits and nonalcoholic beverages under a portfolio of brands such as SweetWater Montauk Shock Top 10 Barrel Breckenridge Blue Point and others and operates production facilities in the United States that supply distributors retailers bars restaurants airports sports venues and airlines including Delta Air Lines.

• Cannabis: This segment cultivates produces distributes and sells medical and adult use cannabis products including flower pre rolls vapes topicals edibles and beverages through facilities in Canada Portugal and Germany and supplies patients in more than 20 countries worldwide.

• Distribution: This segment purchases resells and distributes pharmaceutical and wellness products including medical cannabis through its German subsidiary CC Pharma which supplies public pharmacies hospital pharmacies specialized pharmacies and pharmaceutical wholesalers in Europe and other markets.

• Wellness: This segment produces markets and distributes hemp based foods proteins seeds and functional beverages under brands such as Manitoba Harvest Hemp Yeah Just Hemp Foods and The Humble Seed and sells them through more than 21,000 retail locations in the United States and Canada and in eighteen countries worldwide.

Tilray Brands holds a strong position in each of its markets. In the United States it is ranked as the fourth largest craft brewer according to the Brewers Association. In Canada it generates the highest cannabis revenue among licensed producers and maintains a leading share of the medical and adult use markets. Internationally the company supplies medical cannabis to patients in over twenty countries and operates EU GMP certified facilities in Portugal and Germany. Its distribution arm CC Pharma is one of the leading drug importers in Germany while its wellness division is a top provider of hemp based foods in North America. Competitors include other craft brewers cannabis producers pharmaceutical distributors and hemp food specialists but Tilray Brands differentiates itself through a diversified brand portfolio integrated production and distribution capabilities and a focus on innovation and cost efficiency.

The company serves a broad range of customers including retail consumers hospitality venues and institutional buyers. Its beverage brands are available in nearly fifty thousand off premises retail locations more than thirty thousand restaurants and bars and in venues such as Delta Air Lines flights John F Kennedy International Airport Long Island MacArthur Airport Hartsfield Jackson Atlanta International Airport Denver International Airport and stadiums of the New York Mets Denver Nuggets Atlanta United University of Florida Portland Timbers University of Colorado University of Denver University of Oregon and University of Washington. The distribution segment supplies public pharmacies hospital pharmacies specialized pharmacies and pharmaceutical wholesalers in Germany and other European markets. The wellness segment reaches consumers through grocery stores natural food retailers and direct to consumer channels in the United States Canada and eighteen additional countries.

Investment thesis

Bull case

The recent executive order reclassifying cannabis from Schedule I to Schedule III creates an unprecedented tax and regulatory environment that Tilray can capitalize on. The removal from the 280E tax constraint means the company can now deduct ordinary business expenses such as rent, payroll, and equipment, potentially unlocking a 10‑12 % boost to profitability that has been denied for years. This shift is likely to accelerate capital inflows, improve liquidity, and enhance the attractiveness of Tilray’s balance sheet for future strategic acquisitions. The company’s recent equity raise under the ATM program and its low net‑debt position provide a comfortable runway to deploy these savings on growth initiatives.
Tilray’s multi‑segment platform—cannabis, beverage, wellness, and distribution—offers a powerful diversification moat that reduces exposure to any single market’s volatility. Each segment feeds into the others; for example, cannabis product innovation can be quickly packaged into Delta‑9 beverages, while the distribution network can accelerate both cannabis and wellness product penetration across European drugstores. The company’s 35 % contribution from distribution revenue underscores the strength of its European footprint and the potential for further margin expansion as regulatory barriers ease. This cross‑segment synergy is a key driver that the market often underappreciates.
International growth is poised to accelerate once pending permits in Portugal and Germany materialize. The company’s EU GMP‑certified facilities in Portugal and Germany, coupled with a robust Canadian cultivation base, position it to meet the rising demand for medical cannabis across the EU. The management’s focus on expanding the medical distribution footprint in Germany—tripling its presence in 2026—suggests a clear path to capture a growing share of the projected $10 billion U.S. medical market if the U.S. reclassification proceeds. Tilray’s early entry into the EU GMP supply chain also positions it favorably against competitors that lack compliant infrastructure.
Project 420 has already delivered $25 million in annual savings, moving the company closer to its $33 million target. The project’s SKU rationalization and facility consolidation in the beverage business are expected to lift gross margins by 1‑2 percentage points over the next 12 months. Coupled with the management’s disciplined cost control and lean manufacturing initiatives, the company is on track to reverse the recent margin contraction in cannabis and beverage segments. The incremental margin recovery will translate directly into higher operating cash flow and enhanced shareholder returns.
Tilray’s bold foray into digital assets, including Bitcoin holdings and plans to accept cryptocurrency payments, opens a new revenue stream and strengthens brand appeal among tech‑savvy consumers. The company’s strategy to enable crypto payments for its Delta‑9 beverages and other products aligns with a growing consumer segment that prefers digital currencies for privacy and convenience. While the primary focus remains on core cannabis and beverage businesses, the crypto initiative demonstrates management’s willingness to innovate and diversify risk exposure beyond traditional markets.

The recent executive order reclassifying cannabis from Schedule I to Schedule III creates an unprecedented tax and regulatory environment that Tilray can capitalize on. The removal from the 280E tax constraint means the company can now deduct ordinary business expenses such as rent, payroll, and equipment, potentially unlocking a 10‑12 % boost to profitability that has been denied for years. This shift is likely to accelerate capital inflows, improve liquidity, and enhance the attractiveness of Tilray’s balance sheet for future strategic acquisitions. The company’s recent equity raise under the ATM program and its low net‑debt position provide a comfortable runway to deploy these savings on growth initiatives.
Tilray’s multi‑segment platform—cannabis, beverage, wellness, and distribution—offers a powerful diversification moat that reduces exposure to any single market’s volatility. Each segment feeds into the others; for example, cannabis product innovation can be quickly packaged into Delta‑9 beverages, while the distribution network can accelerate both cannabis and wellness product penetration across European drugstores. The company’s 35 % contribution from distribution revenue underscores the strength of its European footprint and the potential for further margin expansion as regulatory barriers ease. This cross‑segment synergy is a key driver that the market often underappreciates.
International growth is poised to accelerate once pending permits in Portugal and Germany materialize. The company’s EU GMP‑certified facilities in Portugal and Germany, coupled with a robust Canadian cultivation base, position it to meet the rising demand for medical cannabis across the EU. The management’s focus on expanding the medical distribution footprint in Germany—tripling its presence in 2026—suggests a clear path to capture a growing share of the projected $10 billion U.S. medical market if the U.S. reclassification proceeds. Tilray’s early entry into the EU GMP supply chain also positions it favorably against competitors that lack compliant infrastructure.
Project 420 has already delivered $25 million in annual savings, moving the company closer to its $33 million target. The project’s SKU rationalization and facility consolidation in the beverage business are expected to lift gross margins by 1‑2 percentage points over the next 12 months. Coupled with the management’s disciplined cost control and lean manufacturing initiatives, the company is on track to reverse the recent margin contraction in cannabis and beverage segments. The incremental margin recovery will translate directly into higher operating cash flow and enhanced shareholder returns.
Tilray’s bold foray into digital assets, including Bitcoin holdings and plans to accept cryptocurrency payments, opens a new revenue stream and strengthens brand appeal among tech‑savvy consumers. The company’s strategy to enable crypto payments for its Delta‑9 beverages and other products aligns with a growing consumer segment that prefers digital currencies for privacy and convenience. While the primary focus remains on core cannabis and beverage businesses, the crypto initiative demonstrates management’s willingness to innovate and diversify risk exposure beyond traditional markets.

Bear case

Gross margin contraction to 27 % from 30 % last year highlights ongoing pricing and cost pressures that could persist if product mix does not shift back toward higher‑margin categories. The cannabis segment’s margin drop to 36 % from 40 % is largely driven by a heavier mix of infused pre‑rolls and vapes, which have lower pricing power and are vulnerable to regulatory tightening. In the beverage arm, the inclusion of lower‑margin craft acquisition sales has reduced the gross margin from 41 % to 38 %, indicating that the cost‑optimization gains from Project 420 may be insufficient to offset the lower profitability of acquired brands.
Regulatory delays in Portugal and the backlog of permits pose a significant risk to international revenue streams. Management’s acknowledgment that approvals have been “slow” and that the company has only recently begun receiving permits suggests that projected 10 % growth in international cannabis revenue could stall if the regulatory process slows further. A prolonged permit backlog would not only dampen top‑line growth but also increase inventory carrying costs and potentially lead to product obsolescence if consumer demand shifts.
Tilray’s heavy reliance on EU GMP‑certified facilities in Germany and Portugal creates exposure to potential changes in German import rules. The company’s own statement that the German market is “unlikely to change” is an optimistic view; any abrupt policy shift could abruptly cut off a significant distribution channel, forcing the firm to re‑source from alternative suppliers or face reduced volumes. The company’s ability to pivot quickly is constrained by the existing infrastructure, which is tailored to EU GMP compliance, limiting flexibility in the face of regulatory uncertainty.
The beverage segment remains a high‑cost, high‑competition business with thin margins and limited brand equity outside the United States. Despite Project 420’s savings, the company has not yet achieved the scale necessary to compete with established craft breweries and spirits producers, particularly in the premium non‑alcoholic and Delta‑9 categories. The ongoing need to support brand relaunches and retailer relisting can result in significant SG&A expenses, further eroding profitability. This segment’s volatility is a key risk that can offset gains from the cannabis and distribution businesses.
The Canadian market still faces significant excise tax burdens and regulatory constraints that could curb future growth. Management’s emphasis on pricing power is tempered by the broader market’s “pricing down” trend, indicating that consumers remain price‑sensitive. Any tightening of excise tax or additional regulatory restrictions—such as limits on retail channel expansion—could compress margins and stall the company’s ability to maintain its dominant market share.

Gross margin contraction to 27 % from 30 % last year highlights ongoing pricing and cost pressures that could persist if product mix does not shift back toward higher‑margin categories. The cannabis segment’s margin drop to 36 % from 40 % is largely driven by a heavier mix of infused pre‑rolls and vapes, which have lower pricing power and are vulnerable to regulatory tightening. In the beverage arm, the inclusion of lower‑margin craft acquisition sales has reduced the gross margin from 41 % to 38 %, indicating that the cost‑optimization gains from Project 420 may be insufficient to offset the lower profitability of acquired brands.
Regulatory delays in Portugal and the backlog of permits pose a significant risk to international revenue streams. Management’s acknowledgment that approvals have been “slow” and that the company has only recently begun receiving permits suggests that projected 10 % growth in international cannabis revenue could stall if the regulatory process slows further. A prolonged permit backlog would not only dampen top‑line growth but also increase inventory carrying costs and potentially lead to product obsolescence if consumer demand shifts.
Tilray’s heavy reliance on EU GMP‑certified facilities in Germany and Portugal creates exposure to potential changes in German import rules. The company’s own statement that the German market is “unlikely to change” is an optimistic view; any abrupt policy shift could abruptly cut off a significant distribution channel, forcing the firm to re‑source from alternative suppliers or face reduced volumes. The company’s ability to pivot quickly is constrained by the existing infrastructure, which is tailored to EU GMP compliance, limiting flexibility in the face of regulatory uncertainty.
The beverage segment remains a high‑cost, high‑competition business with thin margins and limited brand equity outside the United States. Despite Project 420’s savings, the company has not yet achieved the scale necessary to compete with established craft breweries and spirits producers, particularly in the premium non‑alcoholic and Delta‑9 categories. The ongoing need to support brand relaunches and retailer relisting can result in significant SG&A expenses, further eroding profitability. This segment’s volatility is a key risk that can offset gains from the cannabis and distribution businesses.
The Canadian market still faces significant excise tax burdens and regulatory constraints that could curb future growth. Management’s emphasis on pricing power is tempered by the broader market’s “pricing down” trend, indicating that consumers remain price‑sensitive. Any tightening of excise tax or additional regulatory restrictions—such as limits on retail channel expansion—could compress margins and stall the company’s ability to maintain its dominant market share.

Consolidated Entities Breakdown of Revenue (2025)

Peer comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	106.63 Bn	-5.15	7.33	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	40.81 Bn	25.77	2.35	16.63 Bn
3	ZTS	Zoetis Inc.	31.90 Bn	12.51	3.35	9.05 Bn
4	UTHR	UNITED THERAPEUTICS Corp	24.99 Bn	19.62	7.88	-
5	ACB	Aurora Cannabis Inc	16.83 Bn	5.24	63.04	0.00 Bn
6	NBIX	Neurocrine Biosciences Inc	16.04 Bn	23.79	5.17	-
7	RGC	Regencell Bioscience Holdings Ltd	13.47 Bn	-	-	-
8	HCM	HUTCHMED (China) Ltd	10.84 Bn	23.83	19.76	0.09 Bn

Research Tools

Tilray Brands, Inc. (NASDAQ: TLRY)

About

Investment thesis

Bull case

Bear case

Consolidated Entities Breakdown of Revenue (2025)

Peer comparison

Research Tools

Tilray Brands, Inc. (NASDAQ: TLRY)

About

Investment thesis

Bull case

Bear case

Consolidated Entities Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password